Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
The current standard of care for these patients is to follow and check blood test, though there is no evidence to suggest this is the best practice, Landgren says.
In his presentation at the 17th International Congress on Hematologic Malignancies, Landgren gave an overview of the landscape regard other options in this disease type: ongoing studies, imaging, and molecular profiling studies.
Landgren believes that there will soon be a change in the standard of care, though it is not time to start treating patients outside of clinical trials.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More